Pharma is one of the most closely watched life science stories of 2026 and these 5 Canadian stocks are leading the charge: $BETR.CN $MPH.V $EBM.V $GUD.TO $MDP.TO. Full breakdown: https://t.co/gUWfSm3uO5
Pharma is one of the most closely watched life science stories of 2026 and these 5 Nasdaq stocks are leading the charge: $ANTX $TTRX $KRRO $IRD $ELDN . Full breakdown: https://t.co/bh9ljLvnau
Mayo Clinic built an AI model that predicts pancreatic cancer risk up to 3 years before diagnosis using standard health records. A 50%+ risk score meant an 88% chance of diagnosis within a year. Details: https://t.co/GVtdp1h073
Telix is acquiring Germany's ITM for $1.65B, gaining the world's only commercial-scale producer of lutetium-177, a key cancer treatment isotope. Details: https://t.co/6vMKvQehcS
. @EliLillyandCo 's valuation just topped $1 trillion on GLP-1 sales, while @novonordisk is down 8% YTD after two failed drug trials. Here's what's driving the split: https://t.co/Vd2sHm1Vsf
Humanoid robots just performed live surgery. AI agents are cutting clinical trial costs by millions per study. Here's where the near-term ROI is, and where the moonshots sit: https://t.co/lBJMYfIJMs
Disseminated on behalf of @BriaCell (TSX:BCT,NASDAQ:BCTX).
Nine of 25 patients treated with Bria-IMT since 2022 remain alive, surviving 18 to 47 months in a population where median survival is typically under 12 months. See the data behind BriaCell's immunotherapy approach. Full breakdown: https://t.co/0qgYFfWqZR
Disseminated on behalf of @BriaCell (TSX:BCT,NASDAQ:BCTX). BriaCell's Bria-IMT pivotal trial earned a rare spot on Nature Medicine's list of eleven clinical trials shaping medicine in 2026, with 52% of patients in the latest cohort reaching the one-year survival mark. See what's behind the recognition. Full breakdown: https://t.co/OyamKU3MMo
EliLilly has acquired AtaiBeckley for US$2.8 billion, gaining control of BPL-003, a DMT-derived nasal spray in Phase 3 trials for treatment-resistant depression with Phase 3 results expected in 2029. Read more: https://t.co/XUwWgX9CRt
Zymeworks has agreed to acquire Theravance Biopharma for US$929 million in cash, gaining a 35 percent US profit share in Yupelri, the only once-daily nebulized COPD treatment approved by the https://t.co/98lgg90kIJ more: https://t.co/NglcCHarTz
Merck KGaA has agreed to acquire Bio-Techne for US$11.3 billion in cash, a 36 percent premium and the company's largest deal in a decade. Bio-Techne supplies proteins, antibodies and instruments used in drug discovery and gene therapy globally. Shares surged 20 percent on the news. Read more: https://t.co/0N2F5Z6zrC
Biotech's booming—but you don't have to bet on just one stock. 🔬📈 Biotech ETFs offer diversified exposure to the sector in a single trade. Here are 5 to keep on your radar: https://t.co/E9fRivgXcF #Biotech#ETFs#Investing#HealthcareStocks#LifeScienceInvesting
The pharma industry drives the life sciences sector, powering the development & production of most prescription drugs. 💊
👉 Explore the biggest pharmaceutical stocks to watch! https://t.co/f9DKYRImKR
#LifeScience#PharmaceuticalInvesting
. @TeamRadiopharm is emerging as a key player in the booming radiopharmaceutical space, backed by a cutting-edge tech platform and a robust clinical pipeline. A high-potential opportunity in precision oncology. 🔬📈 #Radiopharmaceuticals#Biotech#RADX#Investing https://t.co/lLDpIwH4T5